Liraglutide FDA Approved

What It Is

Liraglutide is a once-daily, long-acting analog of the human glucagon-like peptide-1 (GLP-1) hormone. It was developed by Novo Nordisk under the code NN2211 and approved by the US FDA in January 2010 as Victoza for type 2 diabetes, then again in December 2014 as Saxenda at higher dose (3.0 mg/day) for chronic weight management in adults with obesity or overweight plus comorbidity. In December 2019 it received pediatric approval for type 2 diabetes in patients aged 10+, and in December 2020 it received pediatric obesity approval for ages 12–17 (Saxenda extension).

Structurally, liraglutide is a 31-amino-acid GLP-1(7-37) analog with two key modifications: a single amino acid substitution (Lys34→Arg34) and a C16 palmitic acid chain attached at Lys26 via a glutamoyl spacer. The fatty acid serves two pharmacokinetic functions — it enables reversible binding to serum albumin (extending plasma half-life from native GLP-1's ~2 minutes to liraglutide's ~13 hours), and it slows absorption from the SubQ depot. The single Arg34 substitution slows enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Together these modifications make liraglutide the first commercially viable once-daily GLP-1 receptor agonist.

Liraglutide's clinical history matters because it is the bridge between the older twice-daily exenatide (Byetta, 2005) and the modern once-weekly GLP-1 era that began with weekly exenatide (Bydureon, 2012) and exploded with semaglutide (Ozempic 2017, Wegovy 2021). Liraglutide is the daily-dosing "second generation" — better tolerability and stronger glycemic effect than twice-daily exenatide, but requiring more injections than the weekly compounds that followed. As of April 2026, liraglutide remains in widespread use for two main reasons: (1) it has the longest cardiovascular outcomes evidence of any GLP-1 in the LEADER trial (Marso et al., NEJM 2016), and (2) its daily dosing produces faster titration and more flexibility than weekly compounds for patients who prefer that pattern.

The SCALE program established liraglutide 3.0 mg as a foundational obesity intervention. SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015; PMID 26132939) showed 8.0% mean weight loss at 56 weeks vs 2.6% placebo in 3,731 patients without diabetes. SCALE Diabetes (Davies et al., JAMA 2015) showed 6.0% in T2D patients. SCALE Maintenance (Wadden 2013) extended these effects. Subsequent trials extended the indication to adolescents (Kelly et al., NEJM 2020; PMID 32320651) and most recently to children 6 to under 12 years of age with obesity (NEJM 2024–2025).

Mechanism of Action

Liraglutide is a near-physiologic GLP-1 receptor agonist. Its effects derive entirely from sustained engagement of the GLP-1 receptor (GLP-1R) and the downstream cascade native GLP-1 already triggers — but at supraphysiologic exposure levels native GLP-1 cannot achieve.

• Pancreatic β-cell GLP-1R activation — Glucose-dependent insulin secretion: liraglutide enhances insulin release in response to glucose without producing inappropriate hypoglycemia in fasted states. The "glucose-dependent" feature is what distinguishes incretin therapy from sulfonylureas.
• α-cell glucagon suppression — Reduces post-prandial glucagon secretion, contributing to lower hepatic glucose output and tighter glycemic control.
• CNS appetite suppression (arcuate nucleus, area postrema) — Liraglutide crosses the blood-brain barrier and activates GLP-1R-expressing POMC/CART neurons in the arcuate nucleus, increasing satiety signaling. Activates the area postrema, which contributes both to reduced hunger and to the early-titration nausea response.
• Gastric emptying delay — Slows gastric emptying, contributing to early satiety and a more gradual post-prandial glucose excursion. This effect attenuates with chronic dosing (tachyphylaxis).
• Weight loss via cumulative caloric deficit — Combined satiety + delayed emptying + reduced hedonic food drive produces sustained ~500 kcal/day deficit in most responders, which translates over months to the 5–10% body weight reduction documented in SCALE.
• Cardiovascular protection — LEADER demonstrated 13% reduction in MACE (CV death, nonfatal MI, nonfatal stroke) over 3.8 years in T2D patients with established CV disease or risk factors. Mechanism likely multi-factorial: weight loss, improved glycemia, BP reduction, anti-inflammatory effects on vascular endothelium, possibly direct cardioprotective signaling.
• Renal protection — Mann et al. NEJM 2017 (LEADER renal substudy) showed reduced new or worsening nephropathy with liraglutide. Reduced macroalbuminuria progression independent of glycemic effect.
• Albumin binding (PK feature, not mechanism) — The C16 fatty acid binds reversibly to serum albumin, providing a depot effect and extending half-life to ~13 hours. Without this feature liraglutide would clear in minutes like native GLP-1.
• BBB penetration — Modest but consistent. CNS GLP-1R activation is the dominant mechanism for the satiety effect; peripheral receptors mediate insulin/glucagon effects.

What the Research Shows

Liraglutide has one of the deepest clinical trial datasets of any chronic-use peptide drug. Major published trials:

• LEAD program (T2D approval, 2007–2010) — Six pivotal Phase 3 trials (LEAD-1 through LEAD-6) establishing T2D efficacy and safety. Basis for 2010 Victoza approval.
• SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015; PMID 26132939) — 56-week double-blind RCT in 3,731 non-diabetic adults with BMI ≥30 or ≥27 with comorbidity. Liraglutide 3.0 mg: −8.0% body weight; placebo −2.6%. ≥5% loss in 63%, ≥10% in 33%. Basis for Saxenda approval.
• SCALE Diabetes (Davies et al., JAMA 2015) — 56-week RCT in T2D patients. 6.0% weight loss at 3.0 mg vs 2.0% placebo, plus HbA1c improvement.
• SCALE Maintenance (Wadden et al., 2013) — Liraglutide for weight maintenance after prior weight loss. Reduced regain vs placebo.
• LEADER (Marso et al., NEJM 2016; PMID 27295427) — Cardiovascular outcomes trial in 9,340 T2D patients with established or high CV risk. Median 3.8 years follow-up. Primary MACE: 13.0% liraglutide vs 14.9% placebo, HR 0.87 (P<0.001 noninferiority, P=0.01 superiority). All-cause mortality 8.2% vs 9.6%, HR 0.85 (P=0.02). Defining CV outcome trial for the GLP-1 class.
• LEADER renal (Mann et al., NEJM 2017) — Reduced incidence of new or worsening nephropathy with liraglutide.
• Pediatric T2D (Tamborlane et al., NEJM 2019) — Liraglutide in 134 patients aged 10–17. HbA1c improvement vs placebo. Basis for pediatric T2D approval.
• Pediatric obesity 12–17 (Kelly et al., NEJM 2020; PMID 32320651) — 56-week RCT in 251 adolescents with obesity. Liraglutide 3.0 mg produced significant BMI standard deviation score reduction vs placebo. Basis for adolescent obesity approval.
• Children 6 to <12 years (NEJM 2024–2025) — Most recent pediatric expansion. Liraglutide in younger children with obesity; favorable BMI reduction; basis for further label expansion.
• Healthy weight maintenance with exercise (Lundgren et al., NEJM 2021) — After diet-induced weight loss, liraglutide alone or combined with exercise was superior to placebo for maintaining weight loss at 1 year. Combined arm best.
• Real-world effectiveness — Multiple registry studies and meta-analyses confirm trial-level effects translate to clinical practice, with attrition and adherence as the main real-world limitations.
• Long-term safety (LEADER + STEP follow-ups) — Multi-year safety data confirms no excess pancreatitis, MTC, or unexpected serious adverse events at the population level.

Human Data

Liraglutide has been administered to hundreds of thousands of patients across 15+ years of approved use. Key human datasets:

• LEAD-1 through LEAD-6 (T2D Phase 3) — Six pivotal trials supporting 2010 Victoza approval.
• SCALE Obesity and Prediabetes — 3,731 patients, 56 weeks. Pi-Sunyer 2015.
• SCALE Diabetes — Davies 2015. 56 weeks in T2D obesity.
• SCALE Maintenance — Wadden 2013. Post-weight-loss maintenance.
• SCALE Sleep Apnea — Liraglutide in obstructive sleep apnea.
• LEADER — 9,340 high-CV-risk T2D patients. 3.8-year median follow-up. Marso 2016.
• LEADER subanalyses — Renal (Mann 2017), prior MI/stroke subgroups, heart failure subgroups.
• Pediatric T2D approval trial (Tamborlane 2019) — 134 patients aged 10–17.
• Adolescent obesity (Kelly 2020) — 251 patients aged 12–17.
• Children 6–<12 obesity (2024–2025) — Most recent label expansion trial.
• Maintenance with exercise (Lundgren 2021) — Combined liraglutide + exercise after diet-induced weight loss.
• Real-world registry data — Multiple post-approval studies confirm effectiveness in routine clinical use.

Dosing from the Literature

Liraglutide has well-defined approved doses for both indications. Titration is essential to manage GI tolerability.

Reconstitution & Storage

Saxenda and Victoza ship as pre-filled multi-dose pen injectors. No reconstitution required. Pens contain 18 mg of liraglutide in 3 mL solution (6 mg/mL).

• Injection sites — Abdomen (2 inches from navel), anterolateral thigh, or upper arm. Rotate sites to prevent localized lipohypertrophy.
• Daily timing — Same time each day. Can be taken with or without food. Many users prefer evening or bedtime to sleep through any nausea peak.
• Missed dose — Take next scheduled dose; do not double-dose. If >3 days missed, restart titration from 0.6 mg per label.
• Needle — Use 32G NovoFine or compatible 4 mm pen needle. Sterile, single-use.
• Inspection — Clear, colorless solution. Discard if cloudy or particulate.

→ Use the Kalios Peptide Calculator for compounded vial dosing

Side Effects & Risks

Liraglutide's safety profile is among the best-characterized of any GLP-1 due to 15+ years of post-marketing experience.

• Nausea — Most common AE. ~40% during titration, declining to ~10–15% at maintenance. Bedtime dosing and slower titration reduce intensity.
• Vomiting — Less common than nausea; ~10% during titration, <5% at maintenance.
• Diarrhea / constipation — Mixed pattern; ~10–20% combined.
• Injection site reactions — Mild; usually transient.
• Heart rate elevation — Modest (~3 bpm increase) and reversible. Not clinically significant in most patients.
• Hypoglycemia — Rare with liraglutide alone (glucose-dependent insulin secretion). Significantly higher when combined with insulin or sulfonylureas — dose-adjust those if combining.
• Pancreatitis — Class boxed warning. Pooled trial data does not show clear excess; case reports exist. Patients with prior pancreatitis should avoid.
• Gallbladder disease — Rapid weight loss raises cholelithiasis/cholecystitis risk. Class effect for all rapid-weight-loss obesity drugs.
• MTC / thyroid C-cell warning — Class boxed warning based on rodent data. Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 is contraindication.
• Pregnancy — Discontinue 2+ months before attempting conception. Animal data suggests teratogenicity at supratherapeutic doses.
• Renal events — Monitor renal function, particularly during severe nausea/vomiting episodes (volume depletion).
• Drug interactions — Delayed gastric emptying affects absorption of oral medications, particularly narrow-therapeutic-index drugs (warfarin, levothyroxine, oral contraceptives in some studies).

Supportive Nutrition & Supplements

Liraglutide produces meaningful weight loss; the structural impact on lean mass and micronutrients depends on what you eat.

• Protein (1.6–2.2 g/kg/day) — The single most-important variable for lean-mass preservation during rapid weight loss. Liraglutide-induced satiety reduces total intake; deliberate protein targeting becomes critical.
• Resistance training — Mechanical load is the other major lean-mass preservation lever. 2–4 sessions/week minimum.
• Electrolytes — Sodium 3–5 g, potassium 3–4 g, magnesium 300–400 mg/day. GI losses during titration drain electrolytes.
• Fiber (25–35 g/day) — Combats constipation; psyllium 5–10 g split dosing helps.
• Vitamin D, B12, multivitamin — Reduced food intake compresses micronutrient exposure; supplement to cover gaps.
• Hydration — 3+ L/day during titration (offset GI losses + GLP-1-mediated thirst suppression).
• Things to avoid — High-fat large-volume meals during titration (amplify nausea), chronic alcohol (additive hepatic and pancreatic risk), NSAID overuse (additive GI risk).

What to Expect — Timeline

• Week 1 (0.6 mg) — Mild appetite reduction; nausea uncommon at this dose.
• Week 2–3 (1.2 → 1.8 mg) — Nausea and early satiety more pronounced. Most adherence failures happen here.
• Week 4–5 (2.4 → 3.0 mg) — Final titration steps. Weight loss begins to accelerate. GI side effects typically start to attenuate.
• Month 2–3 — ~3–5% weight loss. Effect size visible in clothes fit. Sleep and energy often improve.
• Month 4–6 — ~5–7% weight loss in responders. SCALE 56-week endpoint (~8%) is approached.
• Month 6–12 — Plateau begins for many users. Weight loss decelerates; stabilization is the goal.
• Year 1+ — Maintenance phase. Continued dosing maintains weight loss; discontinuation typically produces regain over 6–12 months.
• Non-responders — ~15–20% achieve <5% weight loss at 16 weeks. FDA labeling recommends discontinuation if <4% loss at week 16.

Quick Compare — Liraglutide vs Semaglutide vs Tirzepatide vs Retatrutide

Practical interpretation:

• Liraglutide vs semaglutide — Semaglutide has nearly twice the weight-loss magnitude with weekly dosing; for most obesity-focused patients today, semaglutide is the modern default. Liraglutide retains advantages in pediatric populations (broader pediatric label), in patients who prefer daily titration flexibility, and in CV-risk patients where LEADER's specific evidence applies.
• Liraglutide vs tirzepatide — Tirzepatide more than doubles weight-loss magnitude. Liraglutide remains relevant for patients tirzepatide doesn't tolerate or for whom daily dosing is preferred.
• Pediatric advantage — Liraglutide has the broadest pediatric obesity label, including the recent extension to children 6 to under 12. Semaglutide and tirzepatide are approved for ≥12.
• Cost / access — Liraglutide can be modestly cheaper than newer competitors in some insurance contexts and is often the first GLP-1 covered for obesity in tighter formularies.

→ See semaglutide profile  •  → See tirzepatide profile  •  → See retatrutide profile

Practical User Notes

• Titrate slowly — Compressing the 5-week titration multiplies nausea without changing the long-term outcome.
• Bedtime dosing — Many users find evening/bedtime dosing better tolerated — sleep through the post-injection nausea peak.
• Eat smaller, more frequent meals — Particularly during titration. Large meals + delayed gastric emptying = vomiting.
• Protein first — Hit 30–40 g protein in the first meal of the day before appetite suppression makes additional eating difficult.
• Resistance training — Non-negotiable for lean-mass retention.
• Hydrate — 3+ L/day; both for GI losses and to override the GLP-1-mediated thirst suppression.
• Plan for plateau — Weight-loss plateaus around month 6–8. This is expected, not failure. Maintenance is the goal beyond the loss phase.
• Don't combine with insulin without dose-adjusting — Hypoglycemia risk multiplies. Coordinate with prescribing clinician.
• Pen technique — Same time daily; rotate injection sites; use a fresh needle each dose; prime the pen with each dose.
• If you stop, expect regain — Liraglutide doesn't permanently change appetite biology. Discontinuation generally produces gradual weight regain over 6–12 months unless lifestyle is sustaining the loss.
• Red flags — Severe persistent epigastric pain (rule out pancreatitis), jaundice, sustained tachycardia, intractable vomiting, vision changes, RUQ pain (rule out gallstones). Stop and evaluate.

Bloodwork & Monitoring

• Baseline CMP — Particularly liver, kidney, glucose. Repeat at 3, 6, 12 months.
• HbA1c — Every 3 months in T2D; baseline + annually in non-diabetic obesity.
• Fasting lipid panel — Baseline and at 6 and 12 months.
• Amylase / lipase — Baseline; recheck if any new abdominal pain.
• Calcitonin or thyroid US — Baseline if family history concern; not routine.
• Pregnancy test — In women of reproductive potential.
• Heart rate / BP — Track; modest HR rise is expected.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching liraglutide often also look at these:

Next Steps

Key References

1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939. DOI: 10.1056/NEJMoa1411892.
2. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. PMID: 27295427. DOI: 10.1056/NEJMoa1603827.
3. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. PMID: 28854085.
4. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. PMID: 26284720.
5. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. PMID: 23812094.
6. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. PMID: 32320651.
7. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019;381(7):637-646. PMID: 31034184.
8. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730. PMID: 33951361.
9. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono). Lancet. 2009;373(9662):473-481. PMID: 18819705.
10. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes (LEAD-6). Lancet. 2009;374(9683):39-47. PMID: 19515413.
11. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. PMID: 19853906.
12. Verma S, Bain SC, Honoré JB, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER substudy). J Am Coll Cardiol. 2020;75(13):1505-1517. PMID: 32164886.
13. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. (Head-to-head sema vs lira.)
14. Iepsen EW, Lundgren J, Holst JJ, Madsbad S, Torekov SS. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36. Eur J Endocrinol. 2016;174(6):775-784.
15. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. PMID: 31031702. (Comprehensive Novo Nordisk discovery review.)
16. FDA. Saxenda (liraglutide) prescribing information. December 2014, updated periodically.
17. FDA. Victoza (liraglutide) prescribing information. January 2010, updated periodically.
18. NICE. Liraglutide for the treatment of type 2 diabetes mellitus and weight management. UK National Institute for Health and Care Excellence guidance documents.
19. EMA. Saxenda and Victoza European Public Assessment Reports.
20. Children 6 to <12 Years of Age with Obesity Liraglutide Trial. N Engl J Med. 2024–2025 (NEJMoa2407379-class publications). Pediatric obesity expansion data.